Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy

Erica Steen, Mariam Basilaia, William Kim, Taelor Getz, Jeffrey L. Gustafson, Peter E. Zage

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The RET (REarranged during Transfection) gene, which encodes for a transmembrane receptor tyrosine kinase, is an established oncogene associated with the etiology and progression of multiple types of cancer. Oncogenic RET mutations and rearrangements resulting in gene fusions have been identified in many adult cancers, including medullary and papillary thyroid cancers, lung adenocarcinomas, colon and breast cancers, and many others. While genetic RET aberrations are much less common in pediatric solid tumors, increased RET expression has been shown to be associated with poor prognosis in children with solid tumors such as neuroblastoma, prompting an interest in RET inhibition as a form of therapy for these children. A number of kinase inhibitors currently in use for patients with cancer have RET inhibitory activity, but these inhibitors also display activity against other kinases, resulting in unwanted side effects and limiting their safety and efficacy. Recent efforts have been focused on developing more specific RET inhibitors, but due to high levels of conservation between kinase binding pockets, specificity remains a drug design challenge. Here, we review the background of RET as a potential therapeutic target in neuroblastoma tumors and the results of recent preclinical studies and clinical trials evaluating the safety and efficacy of RET inhibition in adults and children. We also present a novel approach to drug discovery leveraging the chemical phenomenon of atropisomerism to develop specific RET inhibitors and present preliminary data demonstrating the efficacy of a novel RET inhibitor against neuroblastoma tumor cells.

Original languageEnglish (US)
Article number115751
Pages (from-to)115751
JournalBiochemical pharmacology
Volume216
DOIs
StatePublished - Oct 2023

Keywords

  • Atropisomerism
  • Getretinib
  • Neuroblastoma
  • RET
  • Proto-Oncogene Proteins c-ret/genetics
  • Humans
  • Thyroid Neoplasms/drug therapy
  • Neuroblastoma/drug therapy
  • Lung Neoplasms/drug therapy
  • Drug Design
  • Adult
  • Protein Kinase Inhibitors/pharmacology
  • Protein-Tyrosine Kinases
  • Child

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Fingerprint

Dive into the research topics of 'Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy'. Together they form a unique fingerprint.

Cite this